I really would not be concerned in the short term Gavros, in...

I really would not be concerned in the short term Gavros, in fact I expect holders will continue to leave in the absence of news, many see a month as long term and and without news to keep their attention, jump off to chase the next shiny thing. Others will have sold to lock in their profits, I have sold some options so I am now almost free carrying and have a new toy / travel fund.

MPL has not missed a target [so far] it just keeps accumulating ticks. What would be concerning would be adverse side effects and trial participants dropping out, or worse still dyeing. E.g 43% of Relyvrio takers stopped taking it due to side effects, which forms the basis of the class action pending against them.

The CEO is hitting the pavement as we speak. 20-30 million to get a drug approved that once on the marker as early as 2026 that will probably generate that sort of income in a fortnight. [Or less]

No news is MUCH better than bad news.

Cheers.